Abstracts - faqs.org

Abstracts

Retail industry

Search abstracts:
Abstracts » Retail industry

Taking a chance on pharmacists pay off

Article Abstract:

The city of Asheville, NC, implemented a successful pharmacy-based diabetes management program. Under the program, pharmacists provided disease management services to diabetic employees. Employees were encouraged to participate through incentives such as waived co-pays on medications, insulin and syringes. Asheville risk management director John Miall says the program has led to significant benefits including a 50% drop in sick days and increase in the number of employees with normal hemoglobin A1C readings. The city also paid pharmacists between $20 to $80 per consultation.

Author: Zoeller, Janice
Publisher: American Druggist, Inc.
Publication Name: American Druggist
Subject: Retail industry
ISSN: 0190-5279
Year: 1999
Services, Social policy, Pharmacists, Asheville, North Carolina, Patient monitoring, Physiologic monitoring

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Judge dismisses class-action suit

Article Abstract:

Chicago federal court judge Charles Kocoras has dismissed the price-fixing class action lawsuit which some 35,000 independent and chain pharmacies brought against Novartis, Johnson and Johnson, Forest Laboratories and G.D Searle. Judge Kocoras explained the evidences provided by the plaintiffs were meager and insignificant. The plaintiff's general counsel, however, said that Judge Kocoras disallowed much of the plaintiff's evidence, thereby making their case difficult to present. The general counsel indicated that they would appeal Kocoras' decision.

Author: Zoeller, Janice
Publisher: American Druggist, Inc.
Publication Name: American Druggist
Subject: Retail industry
ISSN: 0190-5279
Year: 1999
Cases, Novartis AG, Drugstores, Johnson & Johnson, Forest Laboratories Inc., FRX, Price fixing, JNJ

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Searle weighs Celebrex name change: new Cox-2 has bee been confused with other similarly-named drugs

Article Abstract:

Searle is under pressure to change the name of its Celebrex drug for treating osteoarthritis and rheumatoid arthritis. Celebrex has been mistaken for similarly-named drugs such as the anti-depressant Celexa and IV antiepileptic drug Cerebyx. Another problem for Searle is the linking of Celebrex to 10 deaths and 11 cases of gastrointestinal hemorrhages. Moreover, Celebrex faces competition from the new drug Vioxx.

Author: Zoeller, Janice
Publisher: American Druggist, Inc.
Publication Name: American Druggist
Subject: Retail industry
ISSN: 0190-5279
Year: 1999
Management, Celebrex (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Pharmaceutical industry, G.D. Searle and Co.
Similar abstracts:
  • Abstracts: A long road to justice. The spoils of war: the cat, the house, and now the pension. Breaking cover: the hidden details of pensions are flushed into the open
  • Abstracts: Punching above its weight. Oversexed, overblown and on their way over here. Sleaze hits the high street
  • Abstracts: Moving closer to the heart of Europe. Service sector has its bright spots. Service boom to be wary of
  • Abstracts: The only black candidate in Wales. Dobson offers 'family friendly' shifts to soothe angry nurses. Where Nye Bevan laid the foundation stones
  • Abstracts: You'll never make a lady of Lola. Suzie Hayman had been an only child for 40 years when she got the phone call: 'Hello, it's your sister Carol.'
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.